 |
Under the direction of Dr. Peter K. Law, Cell Transplants Asia Limited (CTAL) invested upwards of $30 million into research and development in an effort to bring Myoblast Transfer Therapy (MTT) to the market; and holds 150 issued or pending patents as depicted below (some cover several countries). CTAL possesses the most comprehensive intellectual properties associated with cell therapy. The patents cover the production of myoblasts, application of myoblasts, production of medium for growth, transport, transplant and storage. CTAL has also patented the automated method to produce myoblasts.
Following are the patents Peter K. Law has been issued over years. This represents the most valuable asset of Cell Transplants Asia Limited as its cutting edge technology remains ahead of the competition.
| Compositions
for and methods of treating muscle degeneration and weaknes |
|
Patent Number
U.S. 5,130,141
(issued)
|
 |
|
Definition
Broad pioneering patent in the field of myogenic cells
and their use for repair of damaged muscle
|
Countries
of Use
United States |
|
|
| Cardiomyocytes
for heart muscles damaged in heart attacks |
Patent Number
Singapore : 99846 (issued)
Aus.: (issued)
U.S. Appl. No. 09/867,519 (pending) |
 |
|
Definition
Method for producing cardiomyocytes capable of proliferation,
comprising providing cardiomyocyte cells; providing
myoblast cells; and mixing the two types of cells under
conditions that allow cell fusion of cardiomyocyte cells
with myoblast cells to form heterokaryotic cardiomyocytes.
|
Countries
of Use
United States
Singapore |
|
|
| Myoblast
therapy for mammalian diseases (1) |
| Patent Number Aus.: 748997 (issued)
China : ZL95192528.8 (issued)
PCT/US: 95/16093 (issued)
Aus.: Appl. No. 45976/96 (issued)
Aus.: Appl. No. 2002300997 (pending)
Can. : Appl. No. 2183167 (pending)
Eur.: Appl. No. 95944088.4 (pending)
|
 |
|
Definition
Compositions and methods for repairing degenerating
cells and replenishing lost cells in patients with hereditary
degenerative diseases, in particular hereditary neuromuscular
disorders
|
Countries
of Use
Australia,
China,
Canada,
Europe (EPO: covers 25 Countries) |
|
|
| Myoblast
therapy for mammalian diseases (2) |
|
Patent Number
U.S. : 6,261,832 (issued)
Singapore : 34490 (issued)
PCT Appl. No. 9801012-7 (pending) |
 |
|
Definition
Myogenic cells that are normal, or genetically or phenotypically
altered are cultured and transplanted into malfunctioning
and/or degenerative tissues or organs to alleviate conditions
that are hereditary, degenerative, debilitating, undesirable,
and/or fatal
|
Countries
of Use
United States
Singapore(a PCT patent: Covers 65 Countries) |
|
|
|
Myoblast transfer therapy for relieving pain and for treating
behavioral and perceptive abnormalities |
|
Patent Number
Eur.: EPO 0898967 (issued)
France : (issued)
Germany : (issued)
UK : (issued)
Italy : (issued)
HK.: HK1016897 (issued)
Mex.: Appl. No. 982560 (issued)
Can. : Appl. No. 2,225,185 (pending)
Jap.: Appl. No. 10-227422 (pending)
U.S. : Appl. No. 09/132,321 (pending)
U.S. : Appl. No. 09/986,344 (pending) |
|
 |
|
Definition
A method of continuously supplying in vivo a peptide
such as an opioid peptide, substance P receptor, or
substance P analog
|
Countries
of Use
Europe (EPO),
Canada,
Hong Kong,
Japan,
Mexico,
United States |
|
|
|
Automated cell processor |
|
Patent Number
U.S. : 6,261,832 (issued)
Singapore : 74036 (issued)
EPO Publication No. 1407788A2 (issued) |
|
 |
|
Definition
An automated instrument for producing a billion mammalian
cells per run using stacked trays and tray tilting to
move fluid into and out of the trays.
|
Countries
of Use
United States,
Singapore (a PCT patent) |
|
|
|
Myoblast therapy for cosmetic treatment |
|
Patent Number
Singapore : 99279 (issued)
Australia : 748997 (issued)
U.S. : Appl. No. 09/005,034 (issued) |
 |
|
Definition
Myoblast cells can be grown up in huge quantities and
added back, to fuse with other muscle cells and adipocytes
(fat cells) to sculpt the body
|
Countries
of Use
Singapore,
Australia,
United States |
|
|
|
Serum containing compositions and methods for cell culture
and therapy |
|
Patent Number
U.S. Provisional Patent Appl.
No. 60/306,426 (pending)
|
Definition
Detailed methods and strategies for successful culture
and manipulation of mammalian cells, and particularly
myogenic cells in non-defined media. Growth media and
procedures presented favor myogenic cell growth at the
expense of fibroblast growth and are particularly useful
for new therapies that combat heart disease and other
muscle disorders
|
Countries
of Use
United States |
|
|
|
Myogenic cell transfer catheter and method |
|
Patent Number
W.O. 02/28470 A1
U.S. 60/231,880 (determined issuable)
PCT/US01/28712 (pending)
Singapore Appl. No. 200301162-4 (pending)
Aus: Appl. No. 2002211230 (pending)
Can: Appl. No. 79029-39 (pending)
|
Definition
Cardiovascular catheters and methods of their use for
automatically injecting large quantities of myogenic
cells for repairing and augmenting muscle and other
tissues. The catheters are "smart" devices
with built in injection timing that allows easy and
more accurate injection of cells from inside a beating
heart for its repair
|
Countries
of Use
United States PCT |
|
|
|
Heart regeneration |
|
Patent Number
U.S. Provisional Patent Application.Foreign
License Granted.
|
Definition
Composition and methods for heart regeneration using
angiomyogenesis
|
Countries
of Use
United States PCT |
|
|
|
Biologic skin repair and enhancement |
|
Patent Number
U.S. Provisional Patent Appl.
No. 60/405,301 (pending)
|
Definition
Composition and methods for beautifying and strengthening
skin
|
Countries
of Use
United States |
|
|
|
Cellular Transplantation for heart regeneration |
|
Patent Number
PCT/US03/95905 (pending)
U.S. Provisional Patent Appl. No. 60/368,563 (pending)
|
Definition
Angiomyogenesis of damaged hearts
|
Countries
of Use
United States PCT |
|
|
|
Mechanisms of myoblast transfer in treating heart failure |
|
Patent Number
PCT (Appl. No. pending)
U.S. Provisional Patent Appl. No. 60/402,050 (pending)
|
Definition
Transduced myoblasts to treat hear muscle degeneration,
baldness and male sexual impotency
|
Countries
of Use
United States PCT |
|
|
|
Myoblast treatment of diseased or weakened organs (pending) |
|
Patent Number
U.S. (Appl. No. pending)
PCT (Appl. No. pending)
|
Definition
Cell therapy to treat and/or augment body structures
|
Countries
of Use
United States |
|
|
Research Licenses
- Cell Therapy Research Foundation, Memphis, TN, USA, 1992-present
- Samsung Cheil Hospital, Seoul, Korea, 1998-2001
- Yonsei University Rehab Institute of Muscular Diseases,
Seoul, Korea,1998-present
- Genesys Research Foundation, Sao Paolo, Brazil, 1998-present
- Duke University, Durham, NC, USA, 2000-present
- Biosense Webster, Newark, NJ, USA, 2000-2001
- Arizona Heart Institute and Arizona Heart Hospital, Phoenix,
AZ, USA, April 2001-present
- National University of Singapore, Singapore, Singapore,
2001
Commercial Licenses
- Bioheart, Inc., Weston, FL, USA, May 2000Conditional
Exclusive License (Non-exclusive license with a first right
of refusal) on Heart Muscle Regeneration and Angiogenesis
- Cell Transplants Singapore Pte Ltd, Singapore, SingaporePerpetual
on all IP issued in Singapore since 1999 to September 2003
- Cell Transplants International, LLC, Memphis, TN USA
|
